U.S. Markets open in 7 hrs 47 mins
  • S&P Futures

    3,936.75
    0.00 (0.00%)
     
  • Dow Futures

    33,631.00
    +6.00 (+0.02%)
     
  • Nasdaq Futures

    11,504.50
    -5.00 (-0.04%)
     
  • Russell 2000 Futures

    1,808.90
    +0.90 (+0.05%)
     
  • Crude Oil

    72.78
    +0.77 (+1.07%)
     
  • Gold

    1,796.90
    -1.10 (-0.06%)
     
  • Silver

    22.84
    -0.08 (-0.34%)
     
  • EUR/USD

    1.0520
    +0.0006 (+0.0526%)
     
  • 10-Yr Bond

    3.4080
    0.0000 (0.00%)
     
  • Vix

    22.68
    +0.51 (+2.30%)
     
  • GBP/USD

    1.2205
    0.0000 (-0.0000%)
     
  • USD/JPY

    136.6620
    +0.1380 (+0.1011%)
     
  • BTC-USD

    16,820.29
    -165.80 (-0.98%)
     
  • CMC Crypto 200

    394.68
    -7.36 (-1.83%)
     
  • FTSE 100

    7,489.19
    -32.20 (-0.43%)
     
  • Nikkei 225

    27,574.43
    -111.97 (-0.40%)
     

Atossa Therapeutics, Inc. to Attend the 24th Annual H.C. Wainwright Global Investment Conference

Atossa Therapeutics, Inc.
Atossa Therapeutics, Inc.

SEATTLE, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to develop innovative medicines in areas of significant unmet medical need in oncology and infectious disease with a current focus on breast cancer and COVID-19, announced today that Kyle Guse, General Counsel & Chief Financial Officer will attend the 24th Annual H.C. Wainwright Global Investment Conference being held on September 12 – 14, 2022 at the Lotte New York Palace.

Mr. Guse will be available for one-on-one meetings. To request a meeting and to register for the conference, click below:

https://hcwevents.com/annualconference/

About Atossa Therapeutics

Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company seeking to develop innovative medicines in areas of significant unmet medical need in oncology and infectious diseases with a current focus on breast cancer and COVID-19.

For more information, please visit www.atossatherapeutics.com

Contact:

Atossa Therapeutics, Inc.
Kyle Guse, General Counsel and Chief Financial Officer
kyle.guse@atossainc.com